Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Title:
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Author:
Cohen, E.E.W. Licitra, L.F. Burtness, B. Fayette, J. Gauler, T. Clement, P.M. Grau, J.J. del Campo, J.M. Mailliez, A. Haddad, R.I. Vermorken, J.B. Tahara, M. Guigay, J. Geoffrois, L. Merlano, M.C. Dupuis, N. Krämer, N. Cong, X.J. Gibson, N. Solca, F. Ehrnrooth, E. Machiels, J.-P.H.